Health
Biotechnology
Pharmaceutical
Ionis Pharmaceuticals
$64.729876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$64.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$2.42 (-3.60%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!
About
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Employees
737
Headquarters
Carlsbad, California
Founded
1989
Market Cap
9.04B
Price-Earnings Ratio
26.13
Dividend Yield
0.00
Average Volume
1.11M
High Today
$68.74
Low Today
$63.80
Open Price
$67.63
Volume
1.29M
52 Week High
$86.58
52 Week Low
$40.91
Collections
Health
Biotechnology
Pharmaceutical
Therapy
Technology
News
Seeking AlphaMay 24
Ionis down 2% on FDA nod for Novartis gene therapy for SMA1
Ionis Pharmaceuticals (IONS -2.2% ) is under modest pressure on the heels of the FDA's OK of Novartis' gene therapy Zolgensma for spinal muscular atrophy Type 1 (SMA1). Ionis out-licensed nusinersen, branded as Spinraza, to Biogen. The FDA approved it in December 2016 for SMA....
Yahoo FinanceMay 14
Ionis Pharmaceuticals Is 40% of the Way There
Ionis Pharmaceuticals (NASDAQ: IONS) started the year off on a positive note, doubling revenue in the first quarter thanks to a large licensing payment from one of its partners.
Yahoo FinanceMay 9
Ionis Pharmaceuticals, Inc. Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) Q1 2019 Earnings Call , 11:30 a.m. ET Operator Good morning and welcome to the Ionis Pharmaceuticals Q1 2019 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Vice President, Investor Relations to lead off the call. Please begin. Wade Walke -- Vice President, Investor Relations Thank you, Gary. Before we begin, I encourage everyone to ...
Price Paid on Robinhood
7% Higher
Right Now
52 Week Low
$40.91
Average Price Paid
$60.24
52 Week High
$86.58
Earnings
-$0.17
$0.09
$0.36
$0.62
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market